retinal lesions

By Targets:	Apoptosis (1) Aquaporin (2) Autophagy (1) Bacterial (1) Complement System (1) Endogenous Metabolite (4) Epoxide Hydrolase (1) Formyl Peptide Receptor (FPR) (1) Reference Standards (2) VEGFR (2)
By Research Areas:	Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (7)
Click Chemistry:	Azide (2)
Oligonucleotides:	Aptamers (1)

Targets Recommended: RPE65

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B1745

Pyridoxylamine 5+ Cited Publications	Endogenous Metabolite	Metabolic Disease
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-P10936A

AQP4 (201-220) TFA	Aquaporin	Neurological Disease Inflammation/Immunology
AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. AQP4 (201-220) TFA can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .

HY-B1745A

Pyridoxylamine dihydrochloride 5+ Cited Publications	Endogenous Metabolite	Metabolic Disease
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-148457

Avacincaptad pegol Izervay	Complement System	Infection Neurological Disease Inflammation/Immunology
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .

HY-P10936

AQP4 (201-220)	Aquaporin	Neurological Disease Inflammation/Immunology
AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .

HY-B1745R

Pyridoxylamine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Pyridoxylamine (Standard) is the analytical standard of Pyridoxylamine. This product is intended for research and analytical applications. Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-178919

N-19004	Formyl Peptide Receptor (FPR) Apoptosis Bacterial	Inflammation/Immunology
N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa .

HY-111159

CP-467688	Autophagy	Neurological Disease
CP-467688 is an orally active retinotoxic agent. CP-467688 induces increased lysosome volume, phagocytosis inhibition and autophagy inhibition in retinal cells. CP-467688 is applicable to the research of retinopathy .

HY-B1745AR

Pyridoxylamine dihydrochloride (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Pyridoxylamine (dihydrochloride) (Standard) is the analytical standard of Pyridoxylamine (dihydrochloride). This product is intended for research and analytical applications. Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-184141

EYE1090	VEGFR	Neurological Disease
EYE1090 is an orally active VEGFR2 inhibitor with an IC₅₀of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .

HY-182372

SH-11037	Epoxide Hydrolase	Neurological Disease
SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization .

HY-184142

EYE1118	VEGFR	Cardiovascular Disease Neurological Disease
EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization .

Cat. No.	상품명	Target	Research Area

HY-P10936A

AQP4 (201-220) TFA	Aquaporin	Neurological Disease Inflammation/Immunology
AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. AQP4 (201-220) TFA can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .

HY-P10936

AQP4 (201-220)	Aquaporin	Neurological Disease Inflammation/Immunology
AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-B1745

Pyridoxylamine 5+ Cited Publications	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Disease markers Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-B1745A

Pyridoxylamine dihydrochloride 5+ Cited Publications	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-B1745R

Pyridoxylamine (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Disease markers Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pyridoxylamine (Standard) is the analytical standard of Pyridoxylamine. This product is intended for research and analytical applications. Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-B1745AR

Pyridoxylamine dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pyridoxylamine (dihydrochloride) (Standard) is the analytical standard of Pyridoxylamine (dihydrochloride). This product is intended for research and analytical applications. Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

Cat. No.	상품명		Classification

HY-184141

EYE1090		Azide
EYE1090 is an orally active VEGFR2 inhibitor with an IC₅₀of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .

HY-184142

EYE1118		Azide
EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization .

Cat. No.	상품명		Classification

HY-148457

Avacincaptad pegol Izervay		Aptamers
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

Inhibitors & Agonists

Peptides

Natural
Products

Click Chemistry

Oligonucleotides

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

retinal lesions

Inhibitors & Agonists

Peptides

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products